X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/difgen-pharmaceuticals-successfully-launches-a-second-product--buprenorphine-transdermal-system-from-its-us-manufacturing-site-aveva-drug-delivery-systems-expanding-its-portfolio-of-manufacturing--marketing-us-made-transdermal--301975456.html
https://www.fiercepharma.com/pharma/indivior-closes-out-yearslong-suboxone-antitrust-case-385m-settlement
https://www.globenewswire.com//news-release/2023/09/19/2745543/0/en/IntelGenx-Provides-Regulatory-Update-for-Xiromed-Partnered-Development-Candidate-Buprenorphine-Buccal-Film.html
https://www.prnewswire.com/news-releases/orexos-patent-win-for-zubsolv-appealed-301883739.html
https://www.prnewswire.com/news-releases/orexo-wins-patent-litigation-for-zubsolv-in-the-us-301868534.html
https://www.globenewswire.com/news-release/2023/06/07/2683810/0/en/Over-40-of-U-S-Pharmacies-Report-No-Buprenorphine-in-Stock-According-to-New-Peer-Reviewed-Study-from-Bicycle-Health-Published-in-JAMA-Network-Open.html
https://www.prnewswire.com/news-releases/fda-approves-new-buprenorphine-treatment-option-for-opioid-use-disorder-301832651.html
https://www.globenewswire.com/news-release/2023/04/27/2656301/0/en/IntelGenx-Announces-Receipt-of-Complete-Response-Letter-from-the-FDA-for-Xiromed-Partnered-Buprenorphine-Buccal-Film.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-22-2023-25079.pdf
https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-9-2022-56129.pdf
https://endpts.com/indivior-fails-to-escape-class-action-lawsuit-in-suboxone-case/
https://www.statnews.com/2022/07/28/buprenorphine-treatment-veterans-opioid-use-disorder-telehealth-covid/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207490
https://www.prnewswire.com/news-releases/indivior-publishes-modeling-data-showing-buprenorphine-may-mitigate-fentanyl-induced-respiratory-depression-in-chronic-opioid-users-301520842.html
https://www.prnewswire.com/news-releases/orexos-lead-product-zubsolv-added-to-ny-state-medicaid-mat-preferred-drug-list-301489356.html
https://www.prnewswire.com/news-releases/research-indicates-sustained-high-plasma-concentrations-of-buprenorphine-reduce-fentanyl-induced-respiratory-depression-in-opioid-tolerant-participants-301470180.html
https://www.globenewswire.com/news-release/2022/01/20/2370128/0/en/BioDelivery-Sciences-Expects-2021-Revenue-at-the-High-End-of-Full-Year-Guidance.html
https://www.nih.gov/news-events/news-releases/offering-buprenorphine-medication-people-opioid-use-disorder-jail-may-reduce-rearrest-reconviction
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-flags-risk-dental-issues-use-opioid-addiction-drug-buprenorphine-2022-01-12/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207486
https://khn.org/news/article/as-overdose-deaths-soar-dea-wary-pharmacies-shy-from-dispensing-addiction-medication/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210272
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211594
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-14-2021-1626258357.pdf
https://www.biospace.com/article/releases/pear-therapeutics-announces-first-participant-enrolled-in-national-institutes-of-health-clinical-trial-investigating-combinations-of-pharmacological-and-behavioral-interventions-to-treat-opioid-use-disorder/?s=105
https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-completes-series-b-financing-and-secures-its-leading-role-in-innovative-antibody-drug-discovery-301320548.html
https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301313130.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210162
https://www.npr.org/2021/04/27/990997759/as-opioid-deaths-surge-biden-team-moves-to-make-buprenorphine-treatment-mainstre
https://www.prnewswire.com/news-releases/acelrx-announces-an-investigator-initiated-study-of-dsuvia-in-patients-taking-buprenorphine-who-require-a-surgical-procedure-301264629.html
https://www.fiercepharma.com/marketing/indivior-faces-uk-lawsuit-from-former-parent-company-over-suboxone-marketing-scheme
https://www.pharmacompass.com/pdf/news/enforcement-report-for-week-of-october-7-2020-1602054141.pdf
https://www.biospace.com/article/releases/indivior-takes-strategic-alignment-actions/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-2-2020-1599053980.pdf
https://www.prnewswire.com/news-releases/braeburn-submits-request-for-final-approval-of-brixadi-buprenorphine-extended-release-injection-for-the-treatment-of-opioid-use-disorder-301068810.html
https://www.prnewswire.com/news-releases/sublocade-long-term-safety-data-published-in-journal-of-clinical-psychopharmacology-301041626.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211586
https://www.statnews.com/2019/12/19/orphan-drug-act-nonprofitability-loophole-needs-closing/
https://www.prnewswire.com/news-releases/new-analysis-from-one-year-study-of-monthly-buprenorphine-extended-release-injections-showed-improved-or-stable-patient-centered-outcomes-300967127.html
https://www.prnewswire.com/news-releases/camurus-announces-new-study-results-showing-superior-patient-reported-outcomes-with-buvidal-versus-standard-of-care-in-treatment-of-opioid-dependence-300965077.html
https://www.prnewswire.com/news-releases/camurus-announces-new-study-results-showing-superior-patient-reported-outcomes-with-buvidal-versus-standard-of-care-in-treatment-of-opioid-dependence-300965077.html
https://www.raps.org/news-and-articles/news-articles/2019/11/fda-revokes-orphan-designation-for-opioid-addictio
https://www.biopharmadive.com/news/teva-opioid-settlement-offer-23-billion-suboxone/565493/
https://www.raps.org/news-and-articles/news-articles/2019/9/product-hopping-ec-hearing-addresses-restriction
Market Place
Share 
